Abstract-Angiotensin II (Ang II) and inflammation are associated with pathogenesis of atrial fibrillation (AF), but the underlying molecular mechanisms of these events remain unknown. The immunoproteasome has emerged as a critical regulator of inflammatory responses. Here, we investigated its role in Ang II-induced AF in immunosubunit PSMB10 (also known as β2i or LMP10) knockout (KO) mice. AF was induced by Ang II infusion (2000 ng/min per kg). PSMB10 expression and trypsin-like activity were increased in atrial tissues and serum from Ang II-treated mice or serum from patients with AF. Moreover, Ang II-infused wild-type (WT) mice had a higher AF and increased atrial fibrosis, reactive oxygen species production, and inflammation compared with saline-treated WT animals. These effects were attenuated in PSMB10 KO mice but were aggravated in recombinant adeno-associated virus serotype 9-PSMB10-treated mice. Administration of IKKβ-specific inhibitor IMD 0354 reduced Ang II-induced AF, reactive oxygen species production, inflammation, and NF-kB (nuclear factor-kB) activation. Mechanistically, Ang II infusion upregulated PSMB10 expression to promote PTEN (phosphatase and tensin homolog deleted on chromosome ten) degradation and AKT1 activation, which not only activated TGF-β-Smad2/3 signaling leading to cardiac fibrosis but also 
A trial fibrillation (AF) is a common arrhythmia associated with heart diseases and increased risk of stroke and death. 1 Experimental animal models and human studies suggest that several major signaling pathways, including the renin-angiotensin system and inflammation, are involved in AF. 2 Angiotensin II (Ang II)-the major effector hormone of the renin-angiotensin system-plays a critical role in the regulation of inflammatory response, oxidative stress, and fibrosis, which are common pathological alterations in AF. 2, 3 Increasing evidence shows that Ang II exerts these actions mainly through AT1 receptor and activation of NF-kB (nuclear factor-kB) signaling. In contrast, inhibition of renin-angiotensin system reduces NF-kB-mediated inflammation and atrial fibrosis. 4 Thus, these data suggest that NF-kB signaling contributes to these inflammatory responses. 5 However, the regulatory mechanisms of NF-kB are not yet fully understood.
The ubiquitin-proteasome system has critical roles in the regulation of protein quality control and various diseases. 6, 7 The 26S proteolytic complex consists of the 20S proteasome and the 19S regulator. The 20S core has 3 standard catalytic subunits, namely β1 (PSMB6 [proteasome subunit beta]), β2 (PSMB7), and β5 (PSMB5) in the inner β-rings. Stimulation with cytokines such as IFN (interferon)-γ induces alternative catalytic β subunits (also termed immunosubunits), including β1i (PSMB9 or LMP2), β2i (PSMB10, MECL-1, or LMP10), and β5i (PSMB8 or LMP7) that replace standard subunits to form new 20S immunoproteasomes. 8 The immunoproteasome has been reported to play an important role in controlling immune responses, oxidative stress, and maintaining cellular protein homeostasis. 8 Also, immunoproteasome regulates specific intracellular signaling pathways, such as NF-kB signaling, more efficiently than the standard proteasome. Deficiency of immunosubunit PSMB8 inhibits NF-kB signaling and production of cytokines. 9 However, there is little information on the role of the immunosubunit PSMB10 in regulating NF-kB signaling and AF.
In this study, we investigated the functional role of immunosubunit PSMB10 in the development of AF in Ang II-infused murine model. The effect of IKK-NF-kB signaling in the
Induction of AF
Mice were anesthetized with 2.5% tribromoethanol (0.02 mL/g; Sigma-Aldrich, United Kingdom). 12 Electrophysiology was performed as previously described. 13, 14 Briefly, the intracardiac pacing was performed by inserting a Millar 1.1F octapolar electrophysiology catheter (Scisense) into the right atrium and ventricle. Inducibility of atrial arrhythmias was tested by applying 5-second bursts through catheter electrodes using an automated stimulator that was part of the data acquisition system (GY6328B; HeNan HuaNan Medical Science and Technology, Ltd). Inducibility of AF was considered positive if at least 2 of 3 pacing trials produced AF. Successful induction of AF was defined as a period of rapid irregular atrial rhythm for at least 1 second.
Delivery of Recombinant Adeno-Associated Virus
Recombinant adeno-associated virus serotype 9 (rAAV9) expressing GFP (green fluorescent protein) alone (rAAV9-GFP) and PSMB10 (rAAV9-PSMB10) were produced by Vigenebio (Shangdong, China) according to the manufacturer's protocol. 15 WT mice were injected with rAAV9-GFP or rAAV9-PSMB10 via tail-vein (100 μl; 5×10 11 vg). Mice were then infused with Ang II (Sigma-Aldrich, St. Louis, MO) at a dose of 2000 ng/kg per minute or saline for additional 3 weeks.
Administration of IKK Inhibitor IMD 0354
The IMD 0354 powder was dissolved in dimethyl sulfoxide, 5% Tween 80, and 0.5% sodium carboxyl methyl cellulose (3 mg/ mL; Sigma-Aldrich, St. Louis, MO). Male WT mice injected with rAAV9-PSMB10 or rAAV9-GFP were intraperitoneally injected with IKK inhibitor IMD 0354 (10 mL/kg, 30 mg/kg QD; Selleck Chemicals) or vehicle from 1 day before the Ang II infusion for 3 weeks. Atrial tissues were removed for further analysis.
Statistical Analyses
All data were analyzed using SPSS 19.0. Comparisons were made by 1-way ANOVA (Student-Newman-Keuls and Bonferroni method), independent t test, or χ 2 test as appropriate. P<0.05 was considered statistically significant.
Results

PSMB10 Expression Is Upregulated in AF
To investigate the role of immunoproteasome in the development of AF, we first examined the proteasome activity. The trypsin-like activity was increased in atrial tissue ( Figure 1A ) and serum ( Figure 1B ) from Ang II-infused mice compared with control. Because both PSMB7 and PSMB10 had the trypsin-like activity, we measured their expression using qPCR (real-time quantitative polymerase chain reaction) analysis and found that PSMB10 expression was upregulated in Ang II-infused atrial tissue, indicating that Ang II-induced trypsin-like activity was because of PSMB10 ( Figure 1C) . Also, the PSMB10 protein was upregulated in Ang II-treated atrial tissues compared with control ( Figure 1D ). Moreover, serum PSMB10 concentration and trypsin-like activity were higher in both patients with paroxysmal and persistent AF compared with controls (Figure 1E and 1F; Table S1 in the online-only Data Supplement).
Deficiency of PSMB10 Reduces Ang II-Induced AF
To investigate whether PSMB10 regulates AF formation, WT and PSMB10 KO mice were infused with Ang II for 3 weeks. Systolic blood pressure was elevated in WT and PSMB10 KO mice, but there was no statistical difference in systolic blood pressure between the 2 groups ( Figure S1 ). The inducibility of AF was increased in Ang II-treated WT mice compared with saline control (70% versus 9%), but this effect was not significantly reduced in PSMB10 KO mice (30% versus 70%; Figure 2A and 2B). Interestingly, the duration of AF was shortened substantially in PSMB10 KO mice compared with WT mice after Ang II infusion ( Figure 2C ). There was no significant difference in AF between the 2 groups after saline treatment (Figure 2A through 2C) .
Knockout of PSMB10 Inhibits Ang II-Induced Atrial Fibrosis
We next examined whether PSMB10 KO influences cardiac fibrosis. Ang II infusion significantly increased atrial fibrosis and expression of collagen I and III compared with control ( Figure 2D and 2E). This increase was reduced in PSMB10 KO mice ( Figure 2D and 2E). Because PTEN-AKT1, TGF-β-Smad2/3, and Smad7 pathways have been shown to play a critical role in tissue fibrosis, [16] [17] [18] [19] we next evaluated whether PSMB10 KO affects these mediators. Ang II infusion reduced PTEN and Smad7 expression but increased p-AKT1, TGF-β, and p-Smad2/3 levels in WT mice, and these proteins had reversed trends in PSMB10 KO mice ( Figure 2F ). To test whether PI3K (phosphoinositide 3-kinase)/AKT1 directly regulates activation of TGF-β and Smad2/3 signaling, we treated primary fibroblasts with PI3K inhibitor wortmannin (100 nmol/L) and then stimulated fibroblasts with Ang II for 24 hours. Western blot analysis showed that Ang IIinduced upregulation of p-AKT1, TGF-β, and p-Smad2/3 was decreased by wortmannin ( Figure S2 ). This was consistent with the findings reported by Voloshenyuk et al. 20 Therefore, KO of PSMB10 attenuates atrial fibrosis likely via blocking PTEN and Smad7 degradation and inhibiting activation of AKT1-mediated TGF-β-Smad2/3 signaling.
Deletion of PSMB10 Attenuates Ang II-Induced Atrial Inflammation and Oxidative Stress
Ang II infusion significantly increased infiltration of inflammatory cells, including Mac-2-positive macrophages ( Figure 3A ) and reactive oxygen species (ROS) production ( Figure 3C ) in WT mice, which was attenuated in PSMB10 KO mice. The mRNA levels of IL (interleukin)-1β, IL-6, NOX (NADPH oxidase) 2, and NOX4 were also lower in PSMB10 KO mice than in WT animals after Ang II infusion ( Figure 3B and 3D). There was no significant difference in these parameters between the 2 groups after saline infusion ( Figure 3A through 3D).
Deficiency of PSMB10 Suppresses Ang II-Induced IkBα Degradation, IKK-NF-kB Activation, and CX43 Expression
We next examined whether PSMB10 affects IKKα/β-IkBα-NF-kB signaling in atrial tissues. Ang II infusion upregulated the levels of p-IKKα/β and p-p65 in WT mice, and this increase was reduced in PSMB10 KO mice ( Figure 3E ). Although p-IkBα was similar between WT and PSMB10 KO mice after Ang II infusion, the reduction of total IkBα protein level in Ang II-treated WT mice was reversed in PSMB10 KO mice ( Figure 3E ). We also evaluated whether PSMB10 regulates ion channel and the gap junction protein expression. 21 After 3 weeks of Ang II infusion, CX43 (connexin 43) expression but not CACNA1C and KCNA5 were upregulated in WT mice, and CX43 expression was attenuated in PSMB10 KO mice ( Figure 3F ), suggesting that PSMB10 deficiency mainly reduces CX43 expression induced by Ang II.
Overexpression of rAAV9-PSMB10 Aggravates Ang II-Induced AF, Fibrosis, Inflammation, and Oxidative Stress
To assess whether overexpression of PSMB10 enhances AF and atrial remodeling in vivo, WT mice were received with rAAV9-PSMB10 or rAAV9-GFP alone by tail-vein injection. Injection of rAAV9-PSMB10 resulted in >90% transfection efficiency of atrial tissues ( Figure S3 ) and increased expression of PSMB10 by 2-fold compared with rAAV9-GFP control ( Figure 4F ). Mice injected with rAAV9 were then subjected to Ang II or saline for 3 weeks. Elevation of systolic blood pressure was similar between rAAV9-PSMB10-and rAAV9-GFP-injected mice ( Figure S4 ). Interestingly, AF duration but not inducibility was enhanced in rAAV9-PSMB10-injected mice compared with rAAV9-GFPtreated control after Ang II infusion (Figure 4A through 4C; lane 4 versus 3). Moreover, Ang II increased atrial fibrosis ( Figure 4D ), infiltration of Mac-2-positive macrophages ( Figure 5A and 5B), ROS production ( Figure 5D and 5E), and expression of collagen I, collagen III, IL-1β, IL-6, NOX2, and NOX4 in rAAV9-GFP-treated animals, and these effects were further accelerated in rAAV9-PSMB10-injected mice ( Figures 4D, 4E , and 5A through 5F; lane 4 versus 3). In contrast to the findings from PSMB10 KO mice, overexpression of rAAV9-PSMB10 further reduced the protein levels of PTEN, Smad7, total and p-IkBα, but increased the levels of p-AKT1, TGF-β, p-Smad2/3, p-IKKα/β, and p-p65 compared with rAAV9-GFP group after Ang II infusion (Figures 4F and 6A ; lane 4 versus 3). In addition, CX43 expression was also enhanced in rAAV9-PSMB10-injected mice compared with rAAV9-GFP-treated control after Ang II infusion ( Figure 6A ; lane 4 versus 3).
Inhibition of IKK Activation Attenuates Ang IIInduced AF
We next determined whether inhibition of IKKβ affects Ang II-induced AF with IMD 0354 (an IKKβ-specific inhibitor). Administration of IMD 0354 to rAAV9-PSMB10-injected 
Inhibition of IKK Activation Reduces Ang IIInduced Inflammation and Oxidative Stress
Administration of IMD 0354 to rAAV9-PSMB10-injected mice greatly reduced Ang II-induced infiltration of Mac-2-positive macrophages ( Figure 5A and 5B), ROS production ( Figure 5D and 5E), and expression of IL-1β, IL-6, NOX2, and NOX4 mRNA ( Figure 5C and 5F) compared with vehicle-treated control (Figure 5A . D, qPCR analysis of NOX (NADPH oxidase) 2 and NOX4 in atrial tissues (n=5 mice per group). E, Western blot analysis of protein levels of p-IKKα/β, IKKα, IKKβ, p-IkBα, IkBα, p-p65, p65, and GAPDH in atrial tissues of WT and PSMB10 KO mice after saline or Ang II infusion and quantification (n=4 mice per group). F, Western blot analysis of protein levels of CACNA1C, KCNA5, CX43 (connexin 43), and GAPDH in each group and quantification (n=4 mice per group). *P<0.05, **P<0.01 vs WT saline-treated mice; #P<0.05, ##P<0.01 vs Ang II-treated WT mice. , and GAPDH in each group and quantification (n=4 mice per group). *P<0.05 vs recombinant adeno-associated virus serotype 9 (rAAV9)-GFP-injected wild-type (WT) mice treated with saline; #P<0.05 vs rAAV9-GFP-injected WT mice treated with Ang II; &P<0.05 vs rAAV9-PSMB10-injected WT mice treated with Ang II; $P<0.05, rAAV9-GFP-injected WT mice treated with Ang II and IMD 0354 vs rAAV9-GFP-injected WT mice treated with Ang II. B, A working model for the regulation of atrial fibrillation (AF) by PSMB10. Ang II infusion markedly increased PSMB10 expression to promote PTEN degradation and AKT1 activation, which not only activates TGF-β-Smad2/3 signaling leading to cardiac fibrosis but also stimulates IKKβ activation-induced IkBα phosphorylation and degradation ultimately causing activation of NF-kB target genes and formation of AF. These effects were prevented by PSMB10 knockout (KO) and IMD 0354.
p-IkBα, p-p65, and CX43 proteins but increased total IkBα level in rAAV9-PSMB10-injected mice ( Figure 6A ; lane 5 versus 4) or in rAAV9-GFP-injected animals ( Figure 6A ; lane 6 versus 3) compared with vehicle-treated control. Together, these data indicate that IKKβ-NF-kB signaling plays a role in Ang II-induced inflammation and oxidative stress leading to AF development.
Discussion
In this study, we used PSMB10 KO and rAAV9-PSMB10-treated mice to show that PSMB10 deficiency inhibited Ang II-induced AF, fibrosis, inflammation, and oxidative stress, which were aggravated in rAAV9-PSMB10-treated mice. The IKKβ inhibitor IMD 0354 blocked Ang II-induced AF, atrial inflammation, and oxidative stress. Mechanistically, Ang II infusion increased PSMB10 expression to promote PTEN degradation and AKT1 activation, which not only activates TGF-β-Smad2/3 signaling leading to cardiac fibrosis but also stimulates IKKβ activation-induced IkBα phosphorylation and degradation ultimately causing activation of NF-kB target genes and formation of AF ( Figure 6B ). Thus, PSMB10 is crucial for Ang II-induced AF.
The standard proteasome is constitutively expressed in most mammalian cells, and expression of immunosubunits is generally lower under basal conditions but can be induced for cells with specific cell exposures. 8 In addition to cytokines (IFN [interferon] and TNF-α [tumor necrosis factor-α]), heat shock, H 2 O 2 , NO, and hyperglycemia also stimulate immunosubunit expression in various cell types. 8 Recent studies indicate that multiple hypertensive stimuli, including Ang II, high-salt, β-adrenergic receptor stimulator isoproterenol, or pressure overload can significantly upregulate expression of both standard and immunoproteasome subunits and proteolytic activity in the heart. [22] [23] [24] [25] Our data showed that PSMB10 expression and its trypsin-like activity were increased in Ang II-treated mice and patients with AF (Figure 1 ), indicating that Ang II can stimulate atrial PSMB10 expression and activity that may contribute to AF. However, the underlying mechanisms remain to be investigated.
Evidence suggests that the immunoproteasome has immune and nonimmune functions, including regulation of inflammation, cell growth, oxidative stress, and muscle mass. 8 It also has been implicated in various diseases, such as cancer, autoimmune neurodegenerative, and cardiovascular diseases. 8 We recently reported that KO of PSMB10 reduced hypertension and cardiac fibrosis in DOCA (deoxycortone acetate)/ salt-treated mice. 22 In this study, our results demonstrated that PSMB10 was important to regulate Ang II-induced AF development. Atrial fibrosis is a hallmark of structural remodeling and AF. 26 Numerous signaling pathways, especially Ang II and TGF-β/Smad, contribute to this process. 5 Animal studies and cell cultured data suggest a novel role for phosphatase PTEN as an inhibitor of fibrosis. Loss of PTEN stimulates activation of AKT, Smad3, and p53 signals and induces the fibrotic response and renal injury. 20 Inhibition of PTEN in vivo also promotes lung fibrosis. 17 Conversely, overexpression of PTEN abrogates TGF-β/Smad2/3 activation and inhibits myofibroblast differentiation in vitro. 17, 18 Thus, PTEN may regulate pathological tissue fibrosis. PTEN stability is regulated by ubiquitination-mediated degradation. 27 Deficiency of immunosubunit β1i blocks PTEN degradation leading to inhibition of AKT activation in ischemic hearts. 28 Here, we provided new evidence showing that PSMB10 KO significantly reduced Ang II-induced atrial fibrosis, PTEN downregulation, and activation of AKT1, TGF-β/Smad2/3 signals ( Figure 2D through 2F ), whereas these effects were aggravated in rAAV9-PSMB10-treated mice (Figure 4D through 4F) . Thus, PSMB10 deficiency inhibits atrial fibrosis likely via PTEN-mediated inhibition of AKT1 and TGF-β/Smad2/3 pathways after Ang II treatment.
Inflammation and oxidative stress promote the development of AF. Inflammatory cells are the primary cellular source of proinflammatory cytokines and ROS that trigger AF and atrial fibrosis. Blockade of inflammation or ROS offers antiarrhythmic benefit in animals and humans.
1,2 However, the protective effect of antioxidants on AF is controversial. 29, 30 Adequately, clinical studies are warranted to clarify the role of antioxidants in prevention of AF. NF-kB has been known to play a key role in regulating the expression of proinflammatory cytokines, (NOX1, NOX2, and NOX4), 31 ion channels (CACNA1G, KCND3, and SCN5A), and gap junction proteins (CX43), 2, 32 which are involved in atrial electric and structural remodeling.
2 Activation of NF-kB is primarily triggered by IKK-induced phosphorylation and subsequent degradation of its inhibitory protein IkBα by the proteasome. 2, 33 Inhibition or deletion of immunosubunit LMP7 (β5i) increases IkBα stability and inhibits NF-kB activation-induced inflammatory diseases. 9, 34 Our recent study showed that KO of PSMB10 blocked IkBα degradation and inhibited NF-kB activation in DOCA/ salt-treated hearts. 22 Here, we also observed that PSMB10 deficiency inhibited Ang II-induced inflammation, ROS production, and expression of IL-1β, IL-6, NOX2, NOX4, and CX43 ( Figure 3) . Importantly, PSMB10 deletion reduced IkBα degradation and inhibited IKKα/β and p65 activation in atrial tissues after Ang II infusion (Figure 3 ), and these effects were enhanced in rAAV9-PSMB10-treated mice (Figures 5 and  6 ). Taken together, these results indicate that loss of PSMB10 attenuates NF-kB-mediated inflammation and oxidative stress mainly by blocking IKK activation and IkBα degradation.
The IKK complex has 2 protein kinases (IKKα and IKKβ) and a regulatory subunit (IKK-γ). 33 IKKβ is considered a primary regulator of classical NF-kB activation, so inhibiting IKKβ activation may be an approach for treating inflammatory diseases. 33, 35 IMD 0354 is a synthetic selective IKKβ inhibitor that prevents cardiovascular disease because it decreases medial hypertrophy and improves survival of pulmonary arterial hypertension. 36 IKKβ inhibition by IMD 0354 protects PM2.5-induced cardiac injury in mice with type 2 diabetes mellitus. 37 Moreover, IMD 0354 treatment inhibits the proinflammatory response and improves adverse cardiac remodeling after myocardial infarction or ischemia/reperfusion injury. 38, 39 IMD 0354 also prevents progression of restenosis after arterial injury. 40 However, the effect of IMD 0354 on Ang II-induced AF remains unclear. Our results showed that IMD 0354 treatment attenuated Ang II-induced AF, inflammation, and oxidative stress (Figures 4 and 5 ) through reducing IkBα degradation and NF-kB-mediated gene expression in rAAV9-PSMB10-treated mice (Figures 5 and 6) , highlighting IKKβ as a promising therapeutic target for treating hypertensive AF.
Perspectives
This report suggests, for the first time, that PSMB10 expression and its trypsin-like activity increased in the atrial tissues and serum from Ang II-infused mice or serum from patients with AF. PSMB10 deficiency reduced AF and atrial remodeling. Thus, PSMB10 may be critical to the development of AF and may be a potential target for therapeutic intervention. More work is needed to confirm our data regarding PSMB10 on AF in other animal models and to evaluate PSMB10 inhibitors as a therapeutic strategy for AF. 
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